

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1 – 45. (canceled)

46. (currently amended) A dosage form comprising:

a ~~formulation~~ an osmotic core comprising a therapeutic agent;

a first membrane in contact with said ~~formulation~~ osmotic core, the first membrane ~~consisting essentially of comprising~~ a hydrophobic substance and a hydrophilic substance, the hydrophilic substance exhibiting an aqueous solubility responsive to osmotic pressure and/or ionic strength of said ~~formulation~~ osmotic core;

a second membrane comprising a semipermeable composition positioned over an outside surface of said first membrane, wherein the second membrane ~~is a semipermeable membrane that~~ maintains its physical and chemical integrity as the dosage form dispenses the therapeutic agent; and

at least one passageway formed across the membranes for dispensing the therapeutic agent from the dosage form.

47. (canceled)

48. (currently amended) The dosage form of claim 46, wherein said first and second membranes form an internal compartment containing the ~~formulation~~ osmotic core.

49-50. (canceled)

51. (original) The dosage form of claim 46, wherein the integrity of the first membrane degrades during operation of the dosage form.

52. (canceled)

53. (previously presented) The dosage form of claim 46, wherein the hydrophilicity of the hydrophobic substance changes in response to changes in osmotic pressure.

54. (original) The dosage form of claim 46, wherein the first membrane is formulated such that the permeability of the first membrane increases in response to a decrease in osmotic pressure.

55. (currently amended) The dosage form of claim 46, wherein the ~~formulation~~ osmotic core, the first membrane, and the second membrane are formulated and configured to deliver the therapeutic agent in an extended, non-declining release profile.

56. (original) The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 30 minutes to about 24 hours.

57. (original) The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 4 hours to about 24 hours.

58. (currently amended) The dosage form of claim 46, wherein the ~~formulation~~ osmotic core, the first membrane, and the second membrane, are formulated and configured to deliver the therapeutic agent in a zero-order release profile.

59. (original) The dosage form of claim 46, further comprising an expandable layer.

60. (currently amended) A method of delivering a therapeutic agent to a subject, the method comprising:

administering a dosage form to the subject, the dosage form comprising:

~~a formulation~~ an osmotic core including the therapeutic agent,

a first membrane ~~that is~~ in contact with the ~~formulation~~ osmotic core, the first membrane ~~consisting essentially of~~ comprising a hydrophobic substance and a hydrophilic substance, the hydrophilic substance exhibiting an aqueous solubility response to osmotic pressure and/or ionic strength of said ~~formulation~~ osmotic core, and

a second membrane comprising a semipermeable composition positioned over an outside surface of said first membrane, wherein the second membrane ~~is a semipermeable membrane that~~ maintains its physical and chemical integrity as the dosage form dispenses the therapeutic agent, and

at least one passageway formed across the membranes for dispensing the therapeutic agent from the dosage form.